Development of Novel Drug Delivery System (DDS) Technologies for Proteomic-Based Drug Development
Authors:
- 1 January 2004
- journal article
- review article
- Published by Pharmaceutical Society of Japan in Biological and Pharmaceutical Bulletin
- Vol. 27 (10) , 1483-1488
Abstract
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societiesKeywords
This publication has 47 references indexed in Scilit:
- Fluorobodies combine GFP fluorescence with the binding characteristics of antibodiesNature Biotechnology, 2003
- Targeting cytokines to inflammation sitesNature Biotechnology, 2003
- Engineering N-glycosylation mutations in IL-12 enhances sustained cytotoxic T lymphocyte responses for DNA immunizationNature Biotechnology, 2002
- Peptide and protein PEGylationBiomaterials, 2001
- PegylationClinical Pharmacokinetics, 2001
- Site-directed polyethylene glycol modification of trichosanthin: Effects on its biological activites, pharmacokinetics, and antigenicityLife Sciences, 1999
- Interleukin 2 receptor‐targeted cytotoxicity. Receptor binding requirements for entry of a diphtheria toxin‐related interleukin 2 fusion protein into cellsEuropean Journal of Immunology, 1990
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Phase I study of recombinant human tumor necrosis factorCancer Chemotherapy and Pharmacology, 1987
- Filamentous Fusion Phage: Novel Expression Vectors That Display Cloned Antigens on the Virion SurfaceScience, 1985